头颈游离组织瓣术后使用酮咯酸不增加皮瓣并发症
该回顾性队列研究比较头颈癌游离皮瓣术后5天内使用与未使用酮咯酸各2280例患者,发现酮咯酸未增加术后出血、皮瓣修整、血管修复、急性肾损伤和胃造瘘管放置风险,30天内并发症未增加。
要点
- 头颈游离皮瓣术后5天内使用酮咯酸与术后出血风险降低相关(RR 0.825)。
- 酮咯酸组皮瓣修整、血管修复、急性肾损伤和胃造瘘管放置风险均未增加。
- 回顾性队列显示术后30天内酮咯酸不增加并发症,但需前瞻性验证。
核心结论
- 头颈游离皮瓣术后5天内使用酮咯酸与30天内并发症增加无关。
研究设计与样本
- 回顾性队列研究,通过ICD-10和CPT代码识别头颈癌游离皮瓣手术患者,酮咯酸组2280例,非酮咯酸组2280例。
主要发现
- 酮咯酸与术后出血风险降低相关(RR 0.825,p=0.016)。
- 酮咯酸与皮瓣修整风险降低相关(RR 0.767,p<0.001)。
- 酮咯酸与血管修复风险降低相关(RR 0.528,p<0.001)。
- 酮咯酸与急性肾损伤风险降低相关(RR 0.664,p=0.003)。
- 酮咯酸与胃造瘘管放置风险降低相关(RR 0.884,p=0.021)。
临床怎么用
- 头颈游离皮瓣术后可考虑使用酮咯酸,但需结合患者个体情况评估。
局限性
- 回顾性队列设计可能存在选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The primary goal of the study is to assess bleeding complications and evaluate ketorolac for its safety in cancer patients undergoing head and neck free-flap surgery. METHODS: Two cohorts of head and neck cancer patients undergoing free-flap surgery were identified using ICD-10 and CPT codes. Cohort 1 received ketorolac within 5 days of surgery (n = 2280); Cohort 2 did not receive ketorolac within 5 days of surgery (n = 2280). Postoperative hemorrhage occurrence and secondary outcomes were assessed. RESULTS: Ketorolac was not associated with increased risk of postoperative hemorrhage (RR: 0.825, p = 0.016), flap revisions (RR: 0.767, p < 0.001), blood vessel repair (RR: 0.528, p < 0.001), AKI (RR: 0.664, p = 0.003), and G-tube placement (RR: 0.884, p = 0.021). CONCLUSIONS: In this retrospective cohort, postoperative ketorolac was not associated with increased complications within the 30-day period.
引用
- Byorth JK, Soule SM, Seliger BJ, et al. Ketorolac Use After Head and Neck Free Tissue Transfer Is Not Associated With Increased Flap Complications. Head Neck. 2026. PMID: 42357844. doi:10.1002/hed.70376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。